Shares of Novavax (NVAX) soared 5.19% in pre-market trading on Thursday, following the company's better-than-expected fourth quarter results and outlook as it transitions away from direct commercialization of its COVID-19 vaccine Nuvaxovid.
For the quarter, Novavax reported an adjusted loss per share of $0.51, narrower than the $1.44 loss a year ago and in line with analysts' estimates. Revenue came in at $88.3 million, beating consensus forecasts of $84.4 million. Sales of the COVID vaccine totaled $49.8 million, down 80% year-over-year as the company ramps down its commercial operations.
Novavax has signed a $1.2 billion licensing deal with Sanofi to hand over rights to sell Nuvaxovid in several markets including the U.S. and Europe starting with the 2025-2026 vaccination season. For 2025, the company expects adjusted licensing, royalties and other revenue to range between $300 million and $350 million, but did not provide forecasts for royalties or milestone payments from Sanofi as it transitions the commercial lead.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.